



INTERIM CONSOLIDATED FINANCIAL REPORT

FOR THE PERIOD ENDED
AUGUST 31, 2017



**INTERIM CONSOLIDATED FINANCIAL REPORT
AS AT AUGUST 31, 2017 AND 2016**

MANAGEMENT COMMENTS	2
INTERIM CONSOLIDATED FINANCIAL STATEMENTS (unaudited)	
Consolidated statements of financial position	3
Interim consolidated statements of changes in equity	4
Interim consolidated statements of net income and comprehensive income	5
Interim consolidated statements of cash flows	6
Notes to the interim consolidated financial statements	7 - 29



To the shareholders of
ZOOMMED INC.

MANAGEMENT COMMENTS

The interim consolidated financial report of ZoomMed Inc. for the three-month periods ended August 31, 2017 and 2016 and all information contained in this interim consolidated financial report is the responsibility of the management and has been approved by the Board of Directors.

The consolidated interim financial report was prepared by the management in accordance with International Financial Reporting Standards ("IFRS") and is consistent with the Company's business.

The Company complies with its TSX Venture Exchange listing agreement. The Company maintains rigorous systems of internal accounting and administrative controls to provide reasonable assurance that the financial information is relevant, reliable and accurate and that the assets are correctly accounted for and protected.

Every year the Board of Directors appoints an Audit Committee composed of a majority of directors who are neither Company officers nor employees. The Audit Committee meets periodically with Management and the external auditors to review their tasks and discuss the audit, accounting policies and related financial matters. The results of their audit are discussed as well. The Audit Committee also reviews the financial statements and the independent auditors' report and recommends their approval by the Board of Directors.

The interim consolidated financial report for the three-month periods ended August 31, 2017 and 2016, has not been reviewed or audited by independent auditors.

December 21, 2017

(Signed) Yves Marmet

**Yves Marmet,
President & Chief Executive Officer**



CONSOLIDATED STATEMENTS OF FINANCIAL POSITION (unaudited)
AS AT AUGUST 31, 2017 AND MAY 31, 2017

	August 31, 2017 (unaudited)	May 31, 2017 (audited)
	\$	\$
ASSETS		
Current assets		
Cash and cash equivalents	12,841	121,665
Receivables (Note 8)	46,522	57,762
Leasehold improvement allowance receivable (Note 9)	7,360	7,360
Prepaid expenses	2,681	4,166
	69,404	190,953
Non-current assets		
Leasehold improvement allowance receivable (Note 9)	22,081	22,081
Fixed assets (Note 10)	142,794	155,365
Intangible assets (Note 11)	-	-
Total assets	234,279	368,399
LIABILITIES		
Current liabilities		
Payables (Note 13)	1,177,810	1,079,511
Loan from Directors (without interest of repayment terms)	125,403	158,057
Loan from a Director (maturing in December 2017)	111,111	108,141
Short-term debt (Note 14)	458,244	439,495
Current portion of long-term debt (Note 15)	45,333	68,000
Current portion of obligations under a finance lease contract (Note 16)	5,143	5,051
	1,923,044	1,858,255
Non-current liabilities		
Provision for loss-making contracts (Note 5)	-	721
Long-term debt (Note 15)	68,000	51,000
Obligations under a finance lease contract (Note 16)	10,951	12,272
Lease inducement	66,525	71,166
Total liabilities	2,068,520	1,993,414
SHAREHOLDERS' EQUITY		
Share capital (Note 19)	25,509,437	25,509,437
Contributed surplus	6,655,185	6,655,185
Deficit	(33,789,637)	(33,789,637)
Total equity	(1,834,242)	(1,625,015)
Total liabilities and equity	234,279	368,399

ON BEHALF OF THE BOARD OF DIRECTORS

(Signed) Yves Marmet, Chairman of the Board and Chief Executive Officer

(Signed) Marie-Hélène Pinard, Director and Chief Financial Officer



**INTERIM CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (unaudited)
FOR THE THREE-MONTH PERIODS ENDED AUGUST 31, 2017 AND 2016**

	Share capital	Contributed surplus	Deficit	Total
	\$	\$	\$	\$
Balance as at May 31, 2017	25,509,437	6,655,185	(33,7879,637)	(1,625,015)
Net result	-	-	(209,227)	(209,227)
Balance as at August 31, 2017	25,509,437	6,655,185	(33,998,864)	(1,834,242)

	Share capital	Contributed surplus	Deficit	Total
	\$	\$	\$	\$
Balance as at May 31, 2016	25,509,437	6,655,185	(31,671,673)	492,949
Net result	-	-	(422,646)	(422,646)
Balance as at August 31, 2016	25,509,437	6,655,185	(32,094,319)	70,303



**INTERIM CONSOLIDATED STATEMENTS OF NET INCOME AND COMPREHENSIVE INCOME (unaudited)
FOR THE THREE-MONTH PERIODS ENDED AUGUST 31, 2017 AND 2016**

	August 31, 2017 (3 months) (unaudited) \$	August 31, 2016 (3 months) (unaudited) \$
CONTINUING OPERATIONS		
REVENUE	10,000	-
OPERATING EXPENSES (Note 17)		
Selling expenses	5,541	80,655
Administrative expenses	136,603	215,906
General operating expenses	4,647	50,346
Development cost	9,866	73,622
Financial expenses	55,093	3,722
	211,750	424,251
LOSS BEFORE INCOME TAXES	(201,750)	(424,251)
INCOME TAXES	-	-
Net loss from continuing operations	(201,750)	(424,251)
Net profit (Net loss) from discontinued operations (Note 4)	(7,477)	1,605
NET RESULT AND COMPREHENSIVE INCOME	(209,227)	(422,646)
Basic and diluted net result per share from continuing operations	(0.001)	(0.003)
Basic and diluted net and comprehensive result per share	(0.001)	(0.003)
WEIGHTED AVERAGE NUMBER OF OUTSTANDING COMMON SHARES	135,591,268	135,591,268



**INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited)
FOR THE THREE-MONTH PERIODS ENDED AUGUST 31, 2017 AND 2016**

	August 31, 2017 (3 months) (unaudited) \$	August 31, 2016 (3 months) (unaudited) \$
OPERATING ACTIVITIES		
Consolidated net and comprehensive income	(209,227)	(422,646)
Net result from discontinued operations in a geographical area	(7,477)	1,605
Net result from continuing operations	(201,750)	(424,251)
Amortization of tangible assets	12,571	12,759
Depreciation of financial expenses	21,729	-
Lease inducement	(4,641)	(4,641)
Net result from discontinued operations	(7,477)	1,605
Provision from loss-making contracts	(721)	(3,887)
	(180,299)	(418,415)
Net change in non-cash operating working capital items (Note 23)	78,371	190,955
Cash flows used in operating activities	(101,928)	(227,460)
FINANCING ACTIVITIES		
Continuing operations		
Repayment of obligations under a finance lease contract	(1,229)	(1,144)
Repayment long-term debt	(5,667)	-
Cash flows from financing activities	(6,896)	(1,144)
INVESTING ACTIVITIES		
Continuing operations		
Acquisition of fixed assets	-	-
Cash flows from investing activities	-	-
NET CHANGE IN CASH AND CASH EQUIVALENTS	(108,824)	(228,604)
CASH AND CASH EQUIVALENTS, BEGINNING OF YEAR	121,665	323,396
CASH AND CASH EQUIVALENTS, END OF YEAR	12,841	94,792

Cash flows used in operating activities include interest expenses of \$16,881 for the three-month period ended August 31, 2017 and \$2,612 for the three-month period ended August 31, 2016.



**NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS (unaudited)
FOR THE THREE-MONTH PERIODS ENDED AUGUST 31, 2017 AND 2016**

1. GENERAL INFORMATION

ZoomMed Inc. ("ZoomMed") was incorporated under the Canada Business Corporations Act on February 24, 2005.

ZoomMed Inc. and its subsidiaries (the "Company") are committed to the development and the marketing of a broad range of computer applications designed for healthcare professionals.

The Company has developed the "ZRx Prescriber", a technological innovative Web application that enables physicians to quickly generate prescriptions. It was designed with the guidance of a committee of physicians. Their requirements called for a speedy and intuitive e-Prescribing application that would facilitate their day-to-day functions, helping them in making the appropriate decisions and choices and protecting them against potential errors and distractions. Accordingly, the ZRx Prescriber was designed with essential PREDICTIVE and PRE-EMPTIVE features that far outweigh what the market had to offer until then. The ZRx Prescriber software behaves similarly to like the latest software such as Google Search or Apple IOS auto-completing keyboard. Unlike static e-Prescribers, the ZRx cloud-based Prescriber solution dynamically analyzes each user's prescribing pattern and displays the expected medication. Furthermore, the pre-emptive features of the ZRx Prescriber, such as drug interactions and potential allergies, are automatically displayed to the physician without him having to solicit and activate an external review module. Most importantly for the very active physician, it allows him to write legible and secure prescriptions and deal with renewals in a few seconds, in fact faster than with a pen.

The ZRx Prescriber is Surescripts® certified and has been tested and certified under the ONC HIT Certification Program (Office of the National Coordinator for Health Information Technology). It is currently in the process of certification for Electronic Prescriptions for Controlled Substances (EPCS).

On November 19, 2015, the Company sold to Familiprix inc., all of the intellectual property rights of its pharmacy laboratory management software "PraxisLab" (Note 4).

Given that the Company has already invested significant efforts to develop the American market, its short-term business plan is to carry on its expansion in this market and then access the United Kingdom market.

ZoomMed Inc. common shares are listed on the TSX Venture Exchange under ZMD symbol.

The Company's registered head office is located at 8005 Du Quartier Blvd., Suite 303, Brossard, Quebec, Canada, J4Y 0N5.

2. BASIS OF PRESENTATION OF FINANCIAL STATEMENTS

The Company prepares its consolidated financial statements in accordance with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB").

These consolidated financial statements have been approved by the Board of Directors on December 21, 2017.

These consolidated financial statements have been prepared in accordance with a going concern. Under the going concern assumption, a Company is viewed as being able to continue its operations in the foreseeable future, and realize its assets and discharge its liabilities in the normal course of operations. However, certain facts and circumstances raise doubts as to this assumption. The Company incurred major losses in recent years, has accumulated an important deficit and its current liquidities may be insufficient to meet its obligations. During the fiscal year, the cash flow shortfall was covered by a loan from a private company, a loan from a Director and the delay in the payment of salaries. After year-end, the Company obtained a loan from a private investor (Note 26) to help meet its obligations.

The continuity of the Company's business depends on its abilities to market, its technology outside of Canada, with a financial partner and to enter into service agreements with partners in Canada. It is not possible to predict, at this point, whether these elements will materialize.



**NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS (unaudited)
FOR THE THREE-MONTH PERIODS ENDED AUGUST 31, 2017 AND 2016**

2. BASIS OF PRESENTATION OF FINANCIAL STATEMENTS (CONT.)

The consolidated financial statements do not reflect adjustments that should be made to the book value of assets and liabilities in the case where the Company would be unable to realize its assets and discharge its liabilities in the normal course of operations.

3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of measurement

These consolidated financial statements have been prepared under the historical cost convention, except for other measurement bases, as indicated in the related notes.

Consolidation

The consolidated financial statements include the accounts of ZoomMed Inc. and its subsidiaries ZoomMed Médical Inc., Praxis Santé Inc. and ZoomMed USA Inc. All intercompany balances and transactions are eliminated upon consolidation.

Revenue recognition

Revenue is recognized to the extent that it is probable that the economic benefits will flow to the Company and the amount can be measured reliably. Revenue comprises the fair value of the consideration received or receivable for services in the ordinary course of the Company's activities.

Interest revenue is recorded on a fiscal year basis according to the effective interest rate method.

Financial Instruments

Financial assets and financial liabilities are initially recognized at fair value and their subsequent measurement is dependent on their classification as described below.

Their classification depends on the purpose aimed for when the financial instruments were acquired or issued, their characteristics and their designation by the Company. Settlement date accounting is used.

All financial assets, except those designated at fair value through profit or loss, are subject to an annual impairment test and written down when there is an indication of impairment. The impairment loss is the excess of the carrying value over fair value and is recorded in the consolidated statements of net income and comprehensive income.

The classification and measurement of the Company's financial instruments are determined as follows:

Financial assets at fair value through net results – All instruments included in this category meet the definition of financial assets held for trading. Financial instruments held for trading are instruments that are held for the purpose of selling in the short term. Instruments in this category include cash and cash equivalents. They are measured initially and subsequently at fair value and changes in fair value are recognized in the consolidated statements of net and comprehensive income in financial income or financial expenses in the period in which they occur. The directly attributable transaction costs are recognized in net and comprehensive income.

Loans and receivables - Loans and receivables are non-derivative financial assets with fixed or determinable payments that are not quoted in an active market. The Company includes in this category, accounts receivable, contingent consideration receivable and Leasehold improvement allowance receivable. Financial instruments included in this category are initially recognized at fair value plus directly attributable transaction costs. Subsequently, loans and receivables are measured at amortized cost using the effective interest method.



**NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS (unaudited)
FOR THE THREE-MONTH PERIODS ENDED AUGUST 31, 2017 AND 2016**

3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONT.)

Other liabilities - Financial instruments included in this category are initially recognized at fair value and transaction costs are deducted from the fair value. Subsequently, other liabilities are measured at amortized cost. The Company includes in this category, accounts payable, loan from a Director, short-term debt and long-term debt.

Cash and cash equivalents

Cash and cash equivalents consist of cash in hand, bank balances, short-term liquid investments with maturities of less than three months and bank overdrafts, if any, which are classified as a category at fair value through net result.

Discontinued operations

A discontinued operation represents a separate major line of business or geographical area of operations that either has been disposed of, or is classified as held for sale. Consolidated statement of financial position items relating to these discontinued operations are presented on specific lines of the annual consolidated financial statements. Comprehensive income items related to these discontinued operations are presented separately in the consolidated financial statements for all fiscal years presented if they are of significance to the Company.

Fixed assets

Fixed assets are initially recorded at cost, including acquisition fees and all the preparation fees directly related to the asset before it can be used, less related research and development investment tax credits. Subsequent to the initial measurement, fixed assets are recorded at cost, less accumulated amortization and depreciation.

Amortization is recognized on a straight-line basis, in line with the assets useful life, as follows:

	Method	Periods
Furniture	Straight-line	5 years
Computer equipment	Straight-line	3 years
IP Telephone system	Straight-line	5 years
Leasehold improvements	Straight-line	5 years

The Company allocates the amount initially recognized in respect of a fixed asset to its significant parts and depreciates separately each such part. Residual values, method of amortization and useful life of the assets are reviewed annually and adjusted if appropriate.

Gains and losses on disposals of fixed assets are determined by comparing the proceeds with the carrying amount of the asset and are included as part of other gains and losses in the consolidated statements of net income and comprehensive income.

Intangible assets

The Company's intangible assets include intellectual properties, licenses and rights, development costs and software with finite useful life. These assets are capitalized and amortized on a straight-line basis in the consolidated statements of comprehensive income over the period of their expected useful life as follows:

	Periods
Software	2 years
Intellectual properties	10 years
Licenses and rights	3 years
Development costs	3 years



**NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS (unaudited)
FOR THE THREE-MONTH PERIODS ENDED AUGUST 31, 2017 AND 2016**

3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONT.)

Research and development expenses

Expenses related to development activities, which do not meet generally accepted criteria for deferral and research activities, are expensed as incurred. Development expenses, which meet generally accepted criteria for deferral are capitalized and amortized against income over the estimated period of benefit.

A distribution license of Rx Vigilance for the US market was recorded at cost and was never amortized. As at May 31, 2017, the Company performed an impairment test and an impairment for the full value of the license was registered (Note 12).

Research and development tax credits

The Company is entitled to scientific research and development tax credits. Tax credits are accounted for using the cost reduction method. Accordingly, tax credits are recorded as a reduction of the related expenses or capital expenditures in the period in which those expenses are incurred, provided there is reasonable assurance that the credits will be realized.

Impairment of long-term non-financial assets

Non-current assets with indefinite useful life are not amortized and are tested for impairment annually. Non-current assets with a finite useful life are assessed for impairment whenever events or changes in circumstances indicate that the carrying amounts of the assets may not be recoverable. Management is required to assess at each reporting date whether there is any indication that an asset may be impaired. Where such an indication exists, the asset's recoverable amount is compared to its carrying value and an impairment loss is recognized for the amount by which the asset's carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset's fair value less costs to sell and value in use. For the purpose of assessing impairment, assets are grouped at the lowest levels for which there are separately identifiable cash flows or cash-generating units ("CGU").

In determining value in use of a given asset or CGU, estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset.

Non-current assets with finite useful life that suffered impairment are reviewed for possible reversal of the impairment if there has been a change, since the date of the most recent impairment test, in the estimates used to determine the impaired asset's recoverable amount. However, an asset's carrying amount, increased due to the reversal of a prior impairment loss, must not exceed the carrying amount that would have been determined, net of depreciation or amortization, had the original impairment not occurred.

Operating Leases

Leases under which the lessor retains substantially all the risks and rewards of ownership are classified as operating leases. Payments under an operating lease (less benefit received from the lessor) are recognized in the consolidated statements of net and comprehensive income on a straight-line basis over the lease term.

Leases under which the Company retains substantially all the risks and rewards of ownership are classified as finance lease contracts. Contracts finance leases are capitalized at the inception of the lease for an amount equal to the fair value of the leased property or, if it is lower, at the present value of payments minimum under the lease. Assets acquired under a finance lease agreement are amortized over the useful life of the asset or over the term of the lease if it is shorter.

Lease inducements

Lease inducements received are recorded at cost and amortized on a straight line basis over the term of the lease (69 months) expiring on March 31, 2021. Depreciation is recognized as a reduction of rent expense.



**NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS (unaudited)
FOR THE THREE-MONTH PERIODS ENDED AUGUST 31, 2017 AND 2016**

3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONT.)

Provisions

Nature of provisioned liabilities

In accordance with IAS 37 Provisions, Contingent Liabilities and Contingent Assets, provisions for risks and expenses are recognized to cover probable outflows of resources that can be estimated and that result from present obligations resulting from past events. In the case where a potential obligation resulting from past events exists, but where occurrence of the outflow of resources is not probable or the estimate is not reliable, these contingent liabilities are disclosed in off-balance sheet commitments and litigation. The provisions are measured based on management's best estimate of net income based on facts known at the reporting date. The provisions include provisions for litigation (tax, legal, employee-related), for returns, for the environment and for loss-making contracts. Litigation is kept under regular review, on a case-by-case basis, by the Company's legal department with the assistance of outside counsel for more significant or complex disputes. A provision is recorded when it becomes probable that a present obligation arising from a past event will require an outflow of resources that can be reliably estimated. The amount of the provision is the best estimate of the outflow of resources required to settle this obligation.

Shareholders' equity

Common shares are classified as equity and are recorded in the Shareholders' Equity at their issuance value. Incremental costs directly attributable to the issuance of shares and stock options are shown in equity as a deduction (as a deficit increase) net of tax from the proceeds. Transactions with shareholders are shown separately in equity.

Income taxes

Income taxes are accounted for, by the Company, based on the consolidated statements of financial position method. Accordingly, future income tax assets and income tax liabilities are measured using the income tax rates that are most likely to apply during the fiscal year where the asset is realized or the liability is settled, based on the income tax rates (and tax regulations) adopted or nearly adopted as at the reporting date. As appropriate, a valuation allowance is recognized to decrease the value of future tax assets to an amount that is more likely than not to be realized.

Employee's benefits

Wages, contributions to government pension plans, paid vacations and sick leaves, bonuses and non-monetary benefits are short-term benefits and are recognized over the period during which the employees of the Company have rendered the related services.

Stock-based compensation

The Company offers a stock-based compensation plan. The Company uses the fair value based method of accounting as regards to stock options granted to its Officers, Directors, Employees and Consultants. The fair value of stock options is determined using the Black-Scholes option-pricing model, and the stock-based compensation costs are recorded in the consolidated statements of net and comprehensive income at the granted date and credited to contributed surplus. Any consideration received by the Company in connection with the exercise of stock options is credited to share capital and contributed surplus component of the stock-based compensation is transferred to share capital upon the issuance of shares.



**NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS (unaudited)
FOR THE THREE-MONTH PERIODS ENDED AUGUST 31, 2017 AND 2016**

3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONT.)

Accounts denominated in foreign currencies

Presentation currency and foreign currency operations – The Canadian dollars is the Company's presentation currency, which is also the Company's functional currency. Foreign currency transactions are translated into the functional currency environment in which the entity operates using the exchange rates prevailing at the dates of the transactions. Assets and liabilities denominated in foreign currencies at the closing date are converted into functional currencies at the exchange rates prevailing at that date. All resulting changes are recognized in the profit or loss, except monetary items included into foreign institution net investment.

Foreign institutions - Foreign institutions' assets and liabilities denominated in functional currencies other than Canadian dollars are converted into Canadian dollars using the exchange rates prevailing at the closing date. Foreign institution revenue and expenses are converted into Canadian dollars using the exchange rates prevailing at the date of the transaction. Shareholders equity is converted at the original effective rate prevailing at the closing date. All resulting changes are recognized in other comprehensive income until the net investment is disposed of, or reclassified in the profit or loss. Since the transition date, no such resulting change was recorded as foreign institutions conversion adjustments.

Basic net earnings and diluted per share

Basic net earnings and diluted per share are calculated using the weighted average number of outstanding common shares during the fiscal year. The Company uses the treasury stock method to determine the dilutive effects of stock options and warrants when cumulating diluted earnings per share. Accordingly, the calculation of diluted earnings per share is made using the treasury stock method, as if all potentially dilutive participating shares had been exercised at the later of the beginning of the period or the date of issuance, as the case may be, and that the funds obtained thereby had been used to purchase common shares of the Company at the average market value of the common shares during the period.

When funds are received, at the date of issuance of dilutive instruments, the net amount is adjusted net of tax expenses related to these instruments.

Diluted net earnings per share from continuing operations is the same as basic net earnings per share due to the anti-dilutive effect of stock options and warrants when the Company suffers losses and / or the stock options and warrants are issued at a premium to the average market price.

4. DISCONTINUED OPERATIONS

Business Line

On November 19, 2015, the Company sold to Familiprix inc., all of the intellectual property rights of its pharmacy laboratory management software "PraxisLab".

Net income from discontinued operations is presented in the consolidated statements of net and comprehensive income according to the table below.

The reclassification consisted of an allocation of income and expenses related to discontinued operations.



**NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS (unaudited)
FOR THE THREE-MONTH PERIODS ENDED AUGUST 31, 2017 AND 2016**

4. DISCONTINUED OPERATIONS (CONT.)

	August 31, 2017 (3 months) (unaudited) \$	August 31, 2016 (3 months) (unaudited) \$
REVENUE	-	-
OPERATING EXPENSES		
Administrative expenses	7,477	-
Financial revenues	-	(1,605)
	7,477	(1,605)
RESULT FROM DISCONTINUED OPERATIONS BEFORE TAXES	(7,477)	1,605
Income tax payable	-	-
NET PROFIT (NET LOSS) FROM DISCONTINUED OPERATIONS	(7,477)	1,605

5. PROVISION FOR LOSS-MAKING CONTRACTS

Provision for loss-making contracts is related to two contracts from discontinued Canadian operations in Toronto. The first contract is related losses from sublease under the lease of Markham and a second lease of a multifunction printer.

	Total \$
Balance as at May 31, 2016	16,225
Use	(15,504)
Balance as at May 31, 2017	721
Use	(721)
Balance as at August 31, 2017	-

6. ACCOUNTING STANDARDS ISSUED BUT NOT YET APPLIED

Financial Instruments

The final version of IFRS 9, issued by the IASB in July 2014, replaces IAS 39 *Financial Instruments: Recognition and Measurement* and IFRIC 9 *Reassessment of Embedded Derivatives* as well as the versions of IFRS 9 issued by the IASB in November 2013, October 2010 and November 2009. The final standard largely retains the classification and measurement requirements and new hedge accounting model included in earlier versions, while introducing a single forward-looking expected credit loss impairment model. The main features introduced in the final version of this new standard are as follows:

- Financial assets are measured at fair value through other comprehensive income if they are held within a business model whose objective is to both collect contractual cash flows and sell financial assets, and the contractual cash flows are solely payments of principal and interest.
- All gains and losses on financial assets measured at fair value through other comprehensive income are recognized in profit or loss when the financial asset is impaired, reclassified to fair value through profit or loss, or derecognized.



**NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS (unaudited)
FOR THE THREE-MONTH PERIODS ENDED AUGUST 31, 2017 AND 2016**

6. ACCOUNTING STANDARDS ISSUED BUT NOT YET APPLIED (CONT.)

- An expected credit loss impairment model is applicable to financial instruments measured at amortized cost or fair value through other comprehensive income, lease receivables, contract assets or loan commitments and financial guarantee contracts. An entity recognizes 12-month expected credit losses if the credit risk of a financial instrument has not increased significantly since initial recognition and lifetime expected credit losses if credit risk has increased significantly since initial recognition.
- IFRS 9 also includes new general hedge accounting requirements, which will result in aligning hedge accounting more closely with risk management. These new requirements do not significantly change the types of hedging relationships or the requirement to measure hedge ineffectiveness. However, they will provide a broader range of hedging strategies for risk management purposes that qualify for hedge accounting, and further require the use of judgment in measuring the effectiveness of a hedging relationship. Specific transitional provisions have been developed to apply the new general hedge accounting requirements.

The Company will have to classify financial assets as subsequently measured either at amortized cost or fair value, on the basis of the Company's business model for managing the financial assets and contractual cash flows of the financial asset. Measurement at amortized cost for most financial liabilities is maintained; however, when an entity measures a financial liability at fair value, the portion of the changes in fair value related to the entity's own credit risk must be presented in other comprehensive income rather than in profit or loss.

IFRS 9 also resulted in consequential amendments to IFRS 7 *Financial Instruments: Disclosures* to include disclosures about an entity's risk management strategy and the effect of hedge accounting on the financial statements. IFRS 9 is effective for annual periods beginning on or after January 1, 2018, and the standard should be applied retrospectively, subject to certain exceptions. Restatement of prior periods is not required and is only permitted if it is possible without the use of hindsight. The Company is currently analyzing the potential effects of adopting this standard on its consolidated financial statements.

IAS 7 – Statement of Cash Flows

IAS 7 Statement of Cash Flows has been revised to incorporate amendments issued by the IASB in January 2016. The amendments require entities to provide disclosures that enable users of financial statements to evaluate changes in liabilities arising from financing activities. The amendments are effective for annual periods beginning on or after January 1, 2017. The Company is currently analyzing the potential effects of adopting this standard on its consolidated statements.

IFRS 15 Revenue from Contracts with Customers

In May 2014, the IASB issued IFRS 15 Revenue from Contracts with Customers, which replaces IAS 11 Construction Contracts, IAS 18 Revenue, IFRIC 13 Customer Loyalty Programmes, IFRIC 15 Agreements for the Construction of Real Estate, IFRIC 18 Transfers of Assets from Customers, and SIC-31 Revenue – Barter Transactions Involving Advertising Services.

The standard provides for a single model that applies to contracts with customers as well as two revenue recognition approaches: at a point in time or over time. The proposed model features a contract-based, five-step analysis of transactions to determine whether, when and how much revenue is recognized. New thresholds have been established for estimates and judgments, which could affect the amount of revenue recognized and/or the timing of recognition.

The new standard applies to contracts with customers. It does not apply to insurance contracts, financial instruments or leases, which are within the scope of other IFRSs. The new standard is effective for the annual period beginning on January 1, 2018. The Company considers that the possible effects of the adoption of this standard will not have a significant impact on its consolidated financial statements.



**NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS (unaudited)
FOR THE THREE-MONTH PERIODS ENDED AUGUST 31, 2017 AND 2016**

6. ACCOUNTING STANDARDS ISSUED BUT NOT YET APPLIED (CONT.)

IFRS 16, "Leases"

In January 2016, the IASB issued IFRS 16, which will replace IAS 17, "Leases." IFRS 16 eliminates the classification as an operating lease and requires lessees to recognize a right-of-use asset and a lease liability in the statement of financial position with exemptions permitted for leases of low-value assets. In addition, IFRS 16 changes the definition of a lease, sets requirements on how to account for the asset and the liability (including complexities such as non-lease elements, variable lease payments and options periods), changes the accounting for sale and leaseback arrangements, largely retains the approach to lessor accounting in IAS 17, and introduces new disclosure requirements. IFRS 16 is effective for annual reporting periods beginning on or after January 1, 2019. Earlier adoption is permitted in certain circumstances. The Company has not yet assessed the impact of this standard on its consolidated financial statements.

IFRIC 22 – Foreign Currency Transactions and Advance Consideration – This new interpretation, issued by the IASB in December 2016, provides guidance on the issue of the "date of the transaction" for the purpose of determining the exchange rate at the time of the transaction, to apply to transactions that are within the scope of IAS 21, Effects of Changes in Foreign Exchange Rates, which involve the receipt or payment of an advance consideration in a foreign currency. The main elements of the interpretation are:

- The entity uses the exchange rate on the date that the foreign currency advance consideration is paid or received to convert the asset, expense or related income on initial recognition.
- When the consideration paid or received in advance consists of multiple payments, the entity determines the date of the transaction for each of them.

The interpretation applies for annual reporting periods beginning on or after January 1, 2018. The Company is currently analyzing the potential effects of adopting this interpretation on its consolidated statements.

IFRIC 23 – Uncertainty over income tax treatments – This new interpretation, issued by the IASB in June 2017, provides guidance as to when it is appropriate to recognize a current tax asset when the taxation authority requires an entity to make an immediate payment related to an amount in dispute. This interpretation applies for annual reporting periods beginning on or after January 1, 2019. The Company is currently analyzing the potential effects of adopting this interpretation on its consolidated statements.

7. CRITICAL ACCOUNTING ESTIMATES AND JUDGMENTS

The preparation of consolidated financial statements in accordance with IFRS often requires management to make estimates about and apply assumptions or subjective judgment to future events and other matters that affect the reported amounts of the Company's assets, liabilities, revenue, expenses, and related disclosures. Assumptions, estimates and judgments are based on historical experience, expectations, current trends and other factors that management believes to be relevant at the time at which the Company's consolidated financial statements are prepared. Management reviews, on a regular basis, the Company's accounting policies, assumptions, estimates, and judgments in order to ensure that the consolidated financial statements are presented fairly and in accordance with IFRS.

Critical accounting estimates and judgments are those that have a significant risk of causing material adjustment and are often applied to matters or outcomes that are inherently uncertain and subject to change. As such, management cautions that future events often vary from forecasts and expectations and that estimates routinely require adjustment.

Management considers the following areas to be those where critical accounting policies affect the significant judgments and estimates used in the preparation of the Company's consolidated financial statements.



**NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS (unaudited)
FOR THE THREE-MONTH PERIODS ENDED AUGUST 31, 2017 AND 2016**

7. CRITICAL ACCOUNTING ESTIMATES AND JUDGMENTS (CONT.)

Estimated useful life

Management assesses fixed assets and intangible assets in line with the assets useful life. The amount and the depreciation schedule related to fixed assets and intangible assets for a given period are affected by the estimated useful life. The estimations are reviewed at least once a year and are updated if the useful life expectations are altered by physical wear, technical and commercial obsolescence.

Fixed assets and intangible assets

The values assigned to the fixed assets and identifiable intangible assets with finite useful life are based on significant estimates and assumptions.

In order to determine whether the fixed assets or identifiable intangible assets have suffered an impairment loss after acquisition or if a fixed asset or an intangible asset, having suffered an impairment loss, may recover its carrying value, management makes assessments based on estimates including, in particular, future risk-adjusted cash flows. Cash flow projections are made according to the Company's forecasts, the economic conditions and business opportunities and therefore are inherently based on judgment.

Future events could cause the assumptions utilized in impairment assessments to change, resulting in a potentially significant effect on the Company's future operating results due to increased impairment charges, or reversals thereof, or adjustments to amortization charges.

Fair value of stock options

Determining the fair value of the stock options requires judgment related to the choice of a pricing model, the estimation of stock price volatility and the expected term of the underlying instruments. Any changes in the estimates or inputs utilized to determine fair value could result in a significant impact on the Company's future operating results or other components of shareholders' equity.

Government assistance

The Company is entitled to government assistance in the form of research and development tax credits and grants. These are applied against related expenses and the cost of the asset acquired. Tax credits are available based on eligible research and development expenses consisting of direct and indirect expenditures and including a reasonable allocation of overhead expenses. Grants are subject to compliance with terms and conditions of the related agreements. Government assistance is recognized when there is reasonable assurance that the Company has met the requirements of the approved grant program or, with regard to tax credits, when there is reasonable assurance that they will be realized.

Definitions of cash generating units

The determination of cash generating units requires judgment in determining the lowest level for which there are largely independent cash inflows generated by the asset group level. This determination could have an impact on the results of impairment testing and, as appropriate, on the impairment charge recorded in the consolidated statements of net income and comprehensive income.

Contingent consideration receivable

Management assess the contingent consideration receivable based on the likelihood of the potential level of achievement of the contractual conditions to be met. As at May 31, 2017, the Company has written off the majority of the balance of the contingent consideration receivable related to the contract with Familiprix.



**NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS (unaudited)
FOR THE THREE-MONTH PERIODS ENDED AUGUST 31, 2017 AND 2016**

7. CRITICAL ACCOUNTING ESTIMATES AND JUDGMENTS (CONT.)

Going concern

The assessment of the Company's ability to commercialize its technology involves judgment. The current situation indicates the existence of a material uncertainty, which may cast significant doubt upon the Company's ability to continue as a going concern. Further information regarding the going concern issue is outlined in note 2.

8. RECEIVABLES

	August 31, 2017	May 31, 2017
	\$	\$
Contingent consideration receivable ⁽¹⁾	12,500	15,000
Sales tax	34,022	42,053
Other receivables	-	709
Total	46,522	57,762

⁽¹⁾ As at August 31, 2017, an amount of \$12,500 (\$15,000 before taxes as at May 31, 2017) was receivable in connection with the transaction with Familiprix Inc.

9. LEASEHOLD IMPROVEMENT ALLOWANCE RECEIVABLE

According to the lease of the new premises, the landlord allocated an improvement allowance of \$25 per ft², repayable over a five-year period in the amount of \$8,582 per year. The first payment was reimbursed on December 31, 2016. If the Company exercises its option to renew the lease, the lessor will allocate an additional improvement allowance in the same amount for the five-year renewal term. As at August 31, 2017, the Company did not record the allowance for the renewal option.

	Total
	\$
Reimbursement to be received	49,913
Discount factor	(6,112)
Discounted amount of the reimbursement to be received as at May 31, 2016	36,801
Cash receipt	(8,582)
Unwinding of discount	1,222
Balance as at May 31, 2017	29,441
Cash receipt	-
Balance as at August 31, 2017	29,441
Current portion	7,360
Long-term portion	22,081
	29,441



**NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS (unaudited)
FOR THE THREE-MONTH PERIODS ENDED AUGUST 31, 2017 AND 2016**

10. FIXED ASSETS

	Furniture	Computer equipment	IP telephone system obligations under a finance lease contract	Leasehold improvements	Total
	\$	\$	\$	\$	\$
Cost					
As at June 1, 2017	55,115	54,552	25,998	197,348	333,013
Acquisitions	-	-	-	-	-
As at August 31, 2017	55,115	54,552	25,998	197,348	333,013
Accumulated amortization					
As at June 1, 2017	41,252	51,165	8,675	76,56	177,648
Amortizations	923	481	1,300	9,867	12,571
As at August 31, 2017	42,175	51,646	9,975	86,423	190,219
Net book value as at August 31, 2017	12,940	2,906	16,023	110,925	142,794
	Furniture	Computer equipment	IP telephone system obligations under a finance lease contract	Leasehold improvements	Total
	\$	\$	\$	\$	\$
Cost					
As at June 1, 2016	55,115	54,122	25,998	197,348	332,583
Acquisitions	-	430	-	-	430
As at May 31, 2017	55,115	54,552	25,998	197,348	333,013
Accumulated depreciation and amortization					
As at June 1, 2016	37,561	48,406	1,300	9,705	96,972
Amortizations	3,691	2,759	5,200	39,470	51,120
Depreciation	-	-	2,175	27,381	29,556
As at May 31, 2017	41,252	51,165	8,675	76,556	177,648
Net book value as at May 31, 2017	13,863	3,387	17,323	120,792	155,365



**NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS (unaudited)
FOR THE THREE-MONTH PERIODS ENDED AUGUST 31, 2017 AND 2016**

11. INTANGIBLE ASSETS

	Software	Licenses and rights	Intellectual properties	Development costs	Total
	\$	\$	\$	\$	\$
Cost					
As at June 1, 2017	4,322	100,000	2,253,934	2,261,549	4,619,805
Acquisitions	-	-	-	-	-
As at August 31, 2017	4,322	100,000	2,253,934	2,261,549	4,619,805
Accumulated depreciation and amortization					
As at June 1, 2017	4,322	100,000	2,253,934	2,261,549	4,619,805
Amortizations	-	-	-	-	-
As at August 31, 2017	4,322	100,000	2,253,934	2,261,549	4,619,805
Net book value as at August 31, 2017	-	-	-	-	-
	Software	Licenses and rights	Intellectual properties	Development costs	Total
	\$	\$	\$	\$	\$
Cost					
As at June 1, 2016	4,322	100,000	2,253,934	2,261,549	4,619,805
Acquisitions	-	-	-	-	-
As at May 31, 2017	4,322	100,000	2,253,934	2,261,549	4,619,805
Accumulated depreciation and amortization					
As at June 1, 2016	4,322	-	2,253,934	2,261,549	4,519,805
Impairment of assets (Note 12)	-	100,000	-	-	100,000
As at May 31, 2017	4,322	100,000	2,253,934	2,261,549	4,619,805
Net book value as at May 31, 2017	-	-	-	-	-

12. DEPRECIATION OF FIXED ASSETS AND INTANGIBLE ASSETS

Valuation method

The Company uses the present value of estimated future cash flows method to determine the value in use of each assets. Impairment tests are performed annually at the same moment, which is at the end of the fiscal year. Since the last tests, the Company has not made any change in the valuation method used to assess impairment of fixed assets and intangible assets.

As at May 31, 2017

Leasehold improvements and telephone system



**NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS (unaudited)
FOR THE THREE-MONTH PERIODS ENDED AUGUST 31, 2017 AND 2016**

12. DEPRECIATION OF FIXED ASSETS AND INTANGIBLE ASSETS (CONT.)

The Company has estimated that, as at May 31, 2017, the delay in the progress of the business plan for the US market did not allow to conclude that the company would be able to recover the carrying amounts of its fixed assets. Impairment was recorded to reduce the book value of its telephone system to the recoverable amount equivalent to the balance of the obligation under a finance lease and the carrying amount of its leasehold improvements to the value in use.

The impact on the value of these two assets is as follows:

	Telephone system \$	Leasehold improvements \$
Cost		
As at June 1, 2016	25,998	197,348
Acquisitions	-	-
As at May 31, 2017	25,998	197,348
Accumulated amortization and depreciation		
As at June 1, 2016	1,300	9,705
Amortizations	5,200	39,470
Depreciation	2,175	27,381
As at May 31, 2017	8,675	76,556
Net book value as at May 31, 2017	17,323	120,792

Rx Vigilance License

The delay in the progress of the business plan for the US market and the lack of financial resources available to realize its plan as at May 31, 2017 led management to conclude that the carrying value of Rx Vigilance license may not be recoverable. An impairment loss was recorded.

The impact on the value of the intangible asset ZRx Prescriber is as follows:

	Licenses and rights \$
Cost	
As at June 1, 2016	100,000
Acquisitions	-
As at May 31, 2017	100,000
Accumulated amortization and depreciation	
As at June 1, 2016	-
Impairment of assets	100,000
As at May 31, 2017	100,000
Net book value as at May 31, 2017	-



**NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS (unaudited)
FOR THE THREE-MONTH PERIODS ENDED AUGUST 31, 2017 AND 2016**

13. PAYABLES

	August 31, 2017	May 31, 2017
	\$	\$
Accounts payable and accrued liabilities	432,837	358,496
Wages and tax deductions	744,974	721,015
Total	1,177,810	1,079,511

14. SHORT-TERM DEBT

On March 13, 2017, the Company entered into a \$500,000 financing agreement with Persistence Capital II. Financing costs of \$75,000 have been disbursed and are amortized over the term of the loan.

The loan bears interest at an annual rate of 12%. Interest is payable monthly. The loan is secured by a conventional hypothec without dispossession in the principal amount of \$500,000 and an additional hypothec of \$220,000 for a total of \$720,000, against the universality of ZoomMed's present and future movable assets, tangible and intangible, of whatever nature and wherever they may be located. The loan is repayable on March 31, 2018.

	Total
	\$
Loan amount	500,000
Financing costs	(75,000)
Amortization of financing cost	33,244
Carrying amount as at May 31, 2017	458,244

15. LONG-TERM DEBT

On July 14, 2015, the Company obtained a loan to finance leasehold improvements with Investissement Québec for a total amount of \$170,000.

The loan bears interest at prime plus 2.5%. The interest is payable monthly. The loan is secured by a conventional without dispossession in the hypothec of principal amount of \$204,000 and an additional hypothec of \$40,800 for a total of \$244,800, against the universality of ZoomMed's present and future movable assets, fixed and intangible, of whatever nature and wherever they may be located.

The loan disbursement was made on February 25, 2016 in a single payment of \$170,000 and the capital is repayable in 30 equal monthly installments of \$5,667 (capital only) maturing February on 28, 2019. On July 3, the Company obtained a 6-month moratorium on capital payments. This moratorium began in August 2017 and postponed the deadline to August 31, 2019.



**NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS (unaudited)
FOR THE THREE-MONTH PERIODS ENDED AUGUST 31, 2017 AND 2016**

15. LONG-TERM DEBT (CONT.)

	Total \$
Balance as at May 31, 2016	170,000
Payments during the period	(51,000)
Balance as at May 31, 2017	119,000
Payments during the period	(5,667)
Balance as at August 31, 2017	113,333
Current portion	45,333
Long-term portion	68,000

Payments to be made in the coming years are as follows:

	\$
2018	45,333
2019	68,000

16. OBLIGATIONS UNDER A FINANCE LEASE CONTRACT

The Company entered into a finance lease contract for the installation and use of an IP telephone system. The contract expires September 15, 2020 and the residual value is \$1. The contract is repayable in monthly principal and interest payments of \$511.

	Total \$
Balance as at May 31, 2016	22,024
Payment during the period	(4,701)
Balance as at May 31, 2017	17,323
Payment during the period	(1,229)
Balance as at August 31, 2017	16,094
Current portion obligations under a finance lease contract	5,143
Long-term portion obligations under a finance lease contract	10,951
	16,094

Minimum finance lease payments for the upcoming twelve-month period are as follows:



**NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS (unaudited)
FOR THE THREE-MONTH PERIODS ENDED AUGUST 31, 2017 AND 2016**

16. OBLIGATIONS UNDER A FINANCE LEASE CONTRACT (CONT.)

	Minimum finance lease payments	
	August 31, 2017	May 31, 2017
	\$	\$
2018	6,134	6,134
2019	6,134	6,134
2020	5,623	6,134
2021	-	1,023
Interest included in the minimum payments	(1,797)	(2,102)
Discounted value of minimum payments under the finance lease	16,094	17,323

17. INFORMATION ON OPERATING EXPENSES

	August 31, 2017 (3 months) (unaudited)	August 31, 2016 (3 months) (unaudited)
	\$	\$
a) Selling expenses :		
Selling expenses	1,000	35,668
Salaries and benefits	1,398	41,797
Amortization of tangible assets	3,143	3,190
	5,541	80,655
b) Administrative expenses :		
Administrative expenses	66,714	91,328
Salaries and benefits	66,746	121,388
Amortization of tangible assets	3,143	3,190
	136,603	215,906
c) General operating expenses :		
Salaries and benefits	1,504	47,156
Amortization of tangible assets	3,143	3,190
	4,647	50,346
d) Development cost :		
Development cost	4,804	11,949
Salaries and benefits	1,919	58,484
Amortization of tangible assets	3,143	3,189
	9,866	73,622



**NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS (unaudited)
FOR THE THREE-MONTH PERIODS ENDED AUGUST 31, 2017 AND 2016**

17. INFORMATION ON OPERATING EXPENSES (CONT.)

	August 31, 2017 (3 months) (unaudited)	August 31, 2016 (3 months) (unaudited)
	\$	\$
e) Financial expenses :		
Interest and bank charges	16,440	891
Interest on short-term and long-term debts	16,577	2,222
Interests on finance lease contracts	304	390
Amortization of financing costs	21,719	-
Exchange rate variation	53	219
	<u>55,093</u>	<u>3,722</u>

18. CONTRACTUAL COMMITMENTS

During the fiscal year ended May 31, 2016, the Company signed a lease agreement for a five-year period with a renewal option for an additional period of five years under the same terms and conditions. As collateral, the Company has granted the lessor a second ranking movable hypothec in the amount of \$114,713, plus an additional hypothec of 20% of that amount on the universality of movable property, present and future of ZoomMed Inc.

As at August 31, 2017, the balance of commitments under leaseholds and operating leases amounts to \$422,034.

Minimum lease payments for each of the next four years are as follows:

	2018	2019	2020	2021
	\$	\$	\$	\$
Leasehold – Head Office	108,998	108,998	108,998	63,582
Multi-function printers	10,486	10,486	10,486	-
	<u>119,484</u>	<u>119,484</u>	<u>119,484</u>	<u>63,582</u>

19. SHARE CAPITAL

a) Authorized

An unlimited number of voting and participating common shares without par value.

b) Declared

	August 31, 2017	May 31, 2017
	\$	\$
135,591,268 common shares as at August 31, 2017 and May 31, 2017	25,509,437	25,509,437

c) Transaction during the three-month period ended August 31, 2017

No transaction occurred during the three-month period ended August 31, 2017.



**NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS (unaudited)
FOR THE THREE-MONTH PERIODS ENDED AUGUST 31, 2017 AND 2016**

19. SHARE CAPITAL (CONT.)

d) Transactions during fiscal year 2017

No transaction occurred during the fiscal year ended May 31, 2017.

20. STOCK OPTION PLAN

The shareholders of the Company adopted a resolution approving the “rolling” stock option plan of 10% at the annual and special meeting of shareholders held November 29, 2016. Under the plan terms, the exercise price of the options will be determined by the Directors of the Company subject to other restrictions described in the plan and some requirements of the TSX Venture Exchange. The maximum period for which an option can be exercise is limited to five years and the exercise price must be paid in full before the issuance of the shares.

The following table summarizes the changes in the plan position for the three-month period ended August 31, 2017 and the fiscal year ended May 31, 2017:

	Options	Average exercise price
		\$
Balance as at June 1, 2016	12,515,000	0.09
Expired	(1,830,000)	0.15
Balance as at May 31, 2017	10,685,000	0.08
Expired	(2,485,000)	0.10
Balance as at August 31, 2017	8,200,000	0.07

Transaction during the three-month period ended August 31, 2017

No transaction occurred during the three-month period ended August 31, 2017.

Transactions during fiscal year ended May 31, 2017

No transaction occurred during the fiscal year 2017.

The following table shows the status of the plan position for the fiscal years ended August 31, 2017 and May 31, 2017.

a) As at August 31, 2017

Outstanding options				Exercisable options	
Number	Weighted average remaining contractual life (months)	Weighted average exercise price	Weighted average fair value	Number	Weighted average exercise price
		\$	\$		\$
7,100,000	29	0.05	0.01	7,100,000	0.05
1,100,000	41	0.21	0.02	1,100,000	0.21
8,200,000	31	0.07	0.01	8,200,000	0.07



**NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS (unaudited)
FOR THE THREE-MONTH PERIODS ENDED AUGUST 31, 2017 AND 2016**

20. STOCK OPTION PLAN (CONT.)

b) As at May 31, 2017

Outstanding options				Exercisable options	
Number	Weighted average remaining contractual life (months)	Weighted average exercise price	Weighted average fair value	Number	Weighted average exercise price
		\$	\$		\$
2,485,000	2	0.10	0.04	2,485,000	0.10
7,100,000	32	0.05	0.01	7,100,000	0.05
1,100,000	44	0.21	0.02	1,100,000	0.21
10,685,000	26	0.08	0.02	10,685,000	0.08

21. FAIR VALUE OF FINANCIAL INSTRUMENTS

	August 31, 2017		May 31, 2017	
	Fair value	Carrying value	Fair value	Carrying value
	\$	\$	\$	\$
Financial assets				
Cash and cash equivalents	12,841	12,841	121,665	121,665
Loans receivables	5,000	5,000	2,500	2,500
Financial liabilities				
Obligations under a finance lease contract	16,094	16,094	17,323	17,323
Short-term debt	486,302	486,302	480,053	483,053
Loan from a Director	111,111	111,111	108,141	108,141
Long-term debt	113,333	113,333	119,000	119,000
Other liabilities	327,328	327,328	329,077	329,077

The fair value of cash and cash equivalents, loans receivables, short-term loans, loan from a Director and other liabilities approximates their carrying value, because of the relatively short maturity of these instruments.

Level 1 - Unadjusted quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis.

Level 2 - Observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3 - Inputs that are supported by little or no market activities and that are significant to the fair value of assets or liabilities.

As at August 31, 2017 and May 31, 2017, the only financial instruments classified in level 1 are cash and cash equivalents, whereas level 2 financial instruments are loans and receivables, leasehold improvement allowance receivable, accounts payable, loan from a Director, short-term loan and long-term debt.



**NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS (unaudited)
FOR THE THREE-MONTH PERIODS ENDED AUGUST 31, 2017 AND 2016**

22. RISK AND UNCERTAINTIES

The Company, through its financial instruments, is exposed to various risks without being exposed to risk concentrations. The Company is primarily exposed to credit risk, interest rate risk, market risk, liquidity risk and key personnel risk.

a) Risks associated with financial instruments

Credit risk

Credit risk is the risk of financial loss for the Company, if a debtor does not meet its obligation. This risk arises mainly from the credit the Company grants its customers in the normal course of its activities.

Credit evaluations are performed continuously and the consolidated statements of financial position reflect a provision for doubtful debts. No qualitative assessment has been made, management has assessed the credit risk was not significant.

Currency risk

The currency risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rate. In the normal course of its operations, the Company is exposed to the risk of variations in the exchange rate of the U.S. dollar.

As at August 31, 2017, the Company has the following balances in converted U.S. dollars: cash: \$176 (\$1,617 as at May 31, 2017). No sensitivity analysis was performed due to the immateriality of the balances denominated in foreign currency.

Interest rate risk

The interest rate risk exists in times of fluctuating rates and when differences are expected in the cash flow matching of assets and liabilities. The Company is exposed to interest rate risk on financial instruments bearing fixed interest rates and variable interest rates. Financial instruments with fixed interest rates expose the Company to a fair value risk and financial instruments at variable interest rates expose the Company to liquidity risk. In addition, it invests part of its liquidity in guaranteed interest rate financial instruments. These financial instruments represent a minimal risk for the Company.

Liquidity risk

Liquidity risk is the risk that the Company will encounter difficulty in meeting obligations associated with financial liabilities. The Company is exposed to this risk mainly regarding its creditors.

In order to meet additional capital requirements, the Company may consider collaborative arrangements and additional public or private financing to fund all or a part of particular product development programs. Private financing could include the incurrence of debt and the issuance of additional equity securities, which could result in dilution to shareholders. There can be no assurance that additional funding will be available. The Company manages this risk by establishing detailed cash forecasts, as well as long-term operating and strategic plans. According to these forecasts, most of its cash flows for operating activities will be generated by operating the ZRx Prescriber in the American market with a financial partner and entering into service agreements with partners in Canada.



**NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS (unaudited)
FOR THE THREE-MONTH PERIODS ENDED AUGUST 31, 2017 AND 2016**

22. RISK AND UNCERTAINTIES (CONT.)

b) Other risks

Market risk

The future performance of the Company is dependent on the continued popularity of its existing products and its ability to develop and introduce products that gain acceptance and satisfy consumer preferences in targeted markets. The popularity of any of its products may decline over time as consumer preferences change or as new competing products are introduced in targeted markets. The development of new systems and their distribution within the targeted market, require significant investments.

Performances linked to the realization of contingent consideration receivable may vary depending on consumer preference changes.

Key personnel risk

Recruiting and retaining qualified personnel is essential to the Company's success. The Company believes that it has been successful in recruiting excellent personnel to help meet its objectives but the Company will have to retain this staff. Although the Company believes that it will be successful in attracting qualified personnel, there can be no assurance to that effect.

23. CAPITAL DISCLOSURES

In regards to capital management, the Company's objective, from the beginning of its operations, is the continuity of its operations in order to carry on with the development and marketing of the ZRx Prescriber, PraxisLab and ZoomMed's communication network, the protection of its assets, while maximizing the shareholders return on investment. The Company is not subject to any externally imposed capital requirements..

The Company defines its capital as the sum of its shareholders equity. The shareholders equity of (\$1,834,242) as at August 31, 2017 and (\$1,625,015) as at May 31, 2017, includes share capital, contributed surplus and deficit. The capital decrease of \$209,227 during the three-month period ended August 31, 2017 is attributable to the operating deficit.

24. RELATED PARTY

Key management compensation

Key management is those persons having authority and responsibility for planning, managing and controlling the Company's activities, including the Directors and Executives. Key management participates to the stock option plan.

For the three-month period ended August 31, 2017 the key management compensation amounted to \$61,925 and \$107,694 for the three-month period ended August 31, 2016. As at August 31, 2017, \$125,043 was payable to key management personnel.

Related party transactions

A director of the Company is a partner in a law firm that acted as legal advisor to the Company. During the three-month period ended August 31, 2017, an amount of \$1,520 (\$938 for the three-month period ended August 31, 2016) was charged by the law firm. An amount of \$10,940 is included in the accounts payable and the accrued liabilities as at August 31, 2017 (\$9,191 as at May 31, 2017).



**NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS (unaudited)
FOR THE THREE-MONTH PERIODS ENDED AUGUST 31, 2017 AND 2016**

24. RELATED PARTY (CONT.)

In September 2016, a Company Director made a \$100,000 loan to the Company. A set-up fee of \$ 15,000 is also payable to this Director in connection with this loan. The total amount of \$115,000 is due December 31, 2017. Financial expenses for the three-month period ending August 31, 2017 include an amount \$2,970 related to this loan.

Related party transactions terms and conditions

The balances at the end of the period are unsecured and bear no interest, since it is a cash settlement. No guaranties were given or received regarding receivables or payables between the related parties. For the three-months periods ended August 31, 2017 and 2016, the Company did not record any impairment in respect of receivables due from related parties. An assessment is performed at each financial period, by examining the related party financial statements and the market in which the related party operates.

These transactions were made on equivalent terms to those prevailing in the case of transactions subject to normal market conditions.

25. NET CHANGE IN NON-CASH OPERATING WORKING CAPITAL ITEMS

	August 31, 2017 (3 months) (unaudited)	August 31, 2016 (3 months) (unaudited)
	\$	\$
Receivables	11,240	90,805
Prepaid expenses	1,485	2,408
Payables	98,300	97,742
Due to directors	(32,654)	-
Total	78,371	190,955

26. SUBSEQUENT EVENT AFTER CLOSING DATE

Financing

On November 2, 2017, the Company has entered into a \$500,000 financing with a private investor dealing at arm's length with ZoomMed. The loan is paid to the Company in installments based on certain events: \$100,000 as an initial deposit, \$250,000 upon execution of the loan agreement and reception of related documents, \$75,000 upon issuance of a press release confirming the filing date of the annual financial statements and \$75,000 following the end of the cease trade on the Company shares. As at December 21, 2017, the Company had received \$425,000.

The loan bears interest at a rate of 12% per annum payable on a quarterly basis. The loan is secured by a movable hypothec in the principal amount of \$600,000 against the universality of its present and future ZoomMed's movable assets, tangible and intangible, of whatever nature and wherever they may be located. The loan will be repayable under certain conditions on November 2, 2018.